Roche Acquires Early-Stage Cancer Drug In US$778mn Deal

In keeping with Roche’s commitment to developing cancer therapies, the company has acquired worldwide exclusive rights to an early stage cancer therapy that is being co-developed by Belgian biopharmaceutical firm Thrombogenics and Swedish antibody developer BioInvent. Under the agreement the two companies will share an upfront payment of EUR50mn (US$78mn) plus up to EUR450mn (US$700mn) based on reaching pre-agreed milestones. The two companies will also receive royalties from eventual product sales, with a 60% share for Thrombogenics and 40% going to BioInvent. The two original developers have retained a co-promotion option covering the Benelux, Nordic and Baltic

addthis_url=”; addthis_title=”; addthis_pub=’jkbioinfo’;

var gaJsHost = ((“https:” == document.location.protocol) ? “https://ssl.” : “http://www.”);
document.write(unescape(“%3Cscript src='” + gaJsHost + “’ type=’text/javascript’%3E%3C/script%3E”));

var pageTracker = _gat._getTracker(“UA-2697320-3”);


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s